Proprotein Convertase 9 Inhibition Professors and Supervisors

Flora Adamsمشاهده پروفایل

پژوهشگر

Vrije Universiteit BrusselBelgium

Flora Adams is a researcher affiliated with Vrije Universiteit Brussel (VUB) in Brussels, Belgium. Her academic work focuses on cardiovascular medicine and pharmaceutical research, with significant contributions to the field of lipid management and novel therapeutic approaches. Dr. Adams' research interests center around cardiovascular therapeutics, particularly focusing on bococizumab, LDL cholesterol management, and proprotein convertase 9 inhibition. Her work has contributed to understanding the safety profiles of novel lipid-lowering agents and their efficacy in high-risk patient populations. The fingerprint analysis of her work shows strong emphasis on bococizumab research (100%), safety assessment (29%), LDL cholesterol management (20%), placebo-controlled studies (19%), and proprotein convertase 9 inhibition (16%). Her most notable publication is the 2017 New England Journal of Medicine article on bococizumab, which has garnered significant attention with 538 citations in Scopus, coverage by 10 news outlets, mentions on 90 X (Twitter) accounts, and references in 5 clinical guideline sources. This research represents important work in the field of cardiovascular risk reduction through novel pharmacological approaches.

پروفایل رسمی دانشگاه

Salah-uddin Ahmedمشاهده پروفایل

استاد

Washington State UniversityUnited States

Salah-uddin Ahmed serves as Professor and Associate Dean for Research and Graduate Education in the Department of Pharmaceutical Sciences at Washington State University College of Pharmacy. His expertise spans rheumatoid arthritis, osteoarthritis, and gout research with emphasis on epigenetic and posttranslational mechanisms driving inflammation. His academic credentials include: PhD in nutrition and chemoprevention, Hamdard University, Department of Toxicology, New Delhi, India Master of Science in toxicology, Hamdard University, New Delhi, India Bachelor of Science in zoology and chemistry, Rajasthan University, Jaipur, India Dr. Ahmed's research investigates cytokine networks (IL-6, IL-1β, TNF-α) in autoimmune diseases, focusing on epigenetic regulation , ubiquitin-proteasome pathways , and microRNA therapeutics . His lab develops targeted inhibitors for rheumatoid arthritis and gout, bridging molecular mechanisms with clinical applications through NIH-funded projects. Current work emphasizes TAK1 signaling and cannabinoid receptor modulation as novel therapeutic avenues. Analysis of his 15 most recent publications reveals consistent focus on synovial fibroblast pathophysiology and inflammatory cascade interruption . Key trends include microRNA-based interventions (e.g., miR-17), natural compounds (EGCG, thymoquinone), and proteasomal degradation strategies targeting Mcl-1 and TRAF proteins. His work demonstrates strong translational potential with multiple in vivo arthritis models. His scientific recognition includes: Graduate Faculty of the Year (2020) Medical Honoree from The Inland Northwest Arthritis Foundation (2019) ACR/REF-Abbott Health Professional Graduate Preceptorship Award (2012) As principal investigator, Dr. Ahmed directs NIH R01-funded microRNA therapy research and mentors F31 predoctoral fellows like Ruby J. Siegel. His $2.5M+ grant portfolio includes Rheumatology Research Foundation projects on guanylate binding proteins in gout. He actively serves on NIH study sections and editorial boards for Arthritis Research & Therapy , shaping field standards through peer review. His laboratory collaborates with University of Washington Rheumatology Division, integrating WSU's pharmaceutical sciences expertise with clinical rheumatology. The team employs multi-omics approaches to identify druggable targets in cytokine signaling, maintaining strong industry partnerships for therapeutic development.

پروفایل رسمی دانشگاه

Gaétan Mayerمشاهده پروفایل

استاد

University of MontrealCanada

Gaétan Mayer is a Professor at the Université de Montréal’s Faculty of Medicine and Faculty of Pharmacy, leading the Cellular and Molecular Biology of Lipoproteins Laboratory at the Montreal Heart Institute (ICM). His research focuses on PCSK9 mechanisms, lipid metabolism, and cardiovascular disease pathogenesis. Education & Affiliations: Directs ICM’s therapeutic targets axis and Discovery & Validation of Therapeutic Targets axis at the Faculty of Pharmacy. Collaborates with the Quebec Drug Research Network (RQRM). Research Interests: Atherosclerosis, LDL cholesterol regulation, metabolic syndrome, and drug discovery targeting PCSK9. Key projects include PCSK9 inhibitors, epigenetic modulation of LDLR, and lipid transport pathways in adipose and liver tissues. Grants & Awards: Recipient of FRQS, CIHR, and Fonds de la Recherche du Québec grants. Notable awards include the Jonathan-Ballon New Researcher Award (2011) and Governor General’s Academic Gold Medal (2000). Labs & Teams: Directs the Cellular and Molecular Biology of Lipoproteins lab, affiliated with ICM and GRUM (Drug Research Group). Supervises 6+ graduate students since 2015, focusing on PCSK9 biology, adipocyte metabolism, and epigenetic therapies.

پروفایل رسمی دانشگاه

Thomas Lagaceمشاهده پروفایل

استادیار

University of OttawaCanada

Dr. Thomas Lagace is an Assistant Professor in the Department of Pathology and Laboratory Medicine and a cross-appointed member of the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. He serves as Director of the Lipoprotein Receptor Biology Laboratory at the University of Ottawa Heart Institute, where he leads research on cellular and molecular mechanisms regulating cholesterol homeostasis and plasma LDL levels. Education: PhD in Biochemistry and Molecular Biology (2004), Dalhousie University Postdoctoral Fellowships: Natural Sciences and Engineering Research Council (NSERC) and Canadian Institutes of Health Research (CIHR) Research Interests: Dr. Lagace investigates how LDL receptor regulation , PCSK9 function , and cholesterol/phospholipid trafficking influence cardiovascular disease risk. His work focuses on molecular chaperoning, receptor degradation pathways, and lipid-protein interactions. Publication Trends: His research spans LDL receptor biology , PCSK9 mechanisms , and phospholipid dynamics , with recent emphasis on therapeutic targets for cholesterol-lowering and molecular pathways in receptor degradation. Scientific Awards: Natural Sciences and Engineering Research Council Fellowship Canadian Institutes of Health Research Fellowship Laboratory and Collaborations: The Lipoprotein Receptor Biology Laboratory, part of the University of Ottawa Heart Institute, includes staff like Research Assistant Tanja Francetic and Graduate Student Samantha Sarkar .

پروفایل رسمی دانشگاه